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Nonviral gene transfer is a rapidly expanding research field in gene therapy. Very efficient gene transfer is achieved in cell culture using either cationic polymers such as poly-l-lysine or polyethylenimine (PEI) or selfassembling cationic lipids. However, in spite of the ever growing family of cationic molecules described to be active in vitro, the in vivo experiments clearly demonstrate a reduced yield in protein expression reported relative to the amount of injected DNA, as compared with the in vitro data. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] This lack of in vivo efficiency has been related to the fact that in many cases cationic lipidmediated gene transfer is inhibited in vitro by serum. 11 Acquiring resistance to this serum-associated inhibition has therefore been actively studied. [11] [12] [13] In vivo, DNA is most often associated with protamine or histones, that condense DNA through their cationic moieties. 14, 15 The roles of these proteins in gene transfer are multiple, and might include DNA protection, as well as a role in intracellular trafficking during infections. 16, 17 Is DNA condensation a requirement for efficient gene transfer? Studies performed with poly-l-lysine showed that alone, this condensation step is insufficient without the addition of endosomolytic agents or targeting moi-eties. [18] [19] [20] [21] [22] [23] [24] Such data led to the concept of DNA-binding domains covalently linked to targeting moieties such as carbohydrates, lectins, integrin-binding sequences or antibody. [24] [25] [26] [27] [28] [29] [30] However, the in vivo efficiency of such targeted vectors is more rarely documented. 31, 32 For cationic lipids and PEI, transfecting capacity might require either an intrinsic capacity to destabilize the endosomes or the association with a helper lipid such as DOPE, [33] [34] [35] [36] and has been shown to be enhanced by the addition of amphiphilic peptides. 37 Some attempts were made to evaluate the potential of combining DNA-compacting agents such as poly-l-lysine or histones with cationic lipids, describing some enhancement of transfection performed in serum-free in vitro conditions, 13, 21, [38] [39] [40] [41] [42] [43] one article reported increased transfection in the presence of serum, 13 and one interesting paper described the use of cationic-lipid-protamine sulfate-DNA complexes for in vivo gene transfer by intravenous administration. 44 Nevertheless, the long poly-l-lysines (100-190 residues) commonly used as DNA-binding or condensing moiety are described as toxic 45 and activate the complement system in vitro. 46 On the other hand, the use of whole proteins such as histones and protamine can be limiting for the scale-up of large gene therapy programs, considering the difficulties associated with the production and purification of recombinant proteins. Additionally, the use of large proteins or polypeptides, either natural or chimeric, would increase the risk of inducing an immune response, either against the protein itself or against the transfection complex as already described for the poly-l-lysine/asialo-orosomucoid/ DNA complexes. 32 An alternative approach to proteins or cationic polymers for combining to cationic lipids, could be the use of a peptide -as short as possible and preferably of natural sequence. This would allow chemical synthesis, thereby reducing the production and purification difficulties. Table 1 summarizes the various peptides used in this study. The sequence KTPKKAKKP corresponds to residues 152-160 of the human histone H1. This highly conserved sequence is repeated in the C terminus of histones H1 from various species, and a dimer alters the conformation of short double-stranded linear DNA fragments. 47 We investigated the ability of monomeric (H9), dimeric (H9-2) and trimeric (H9-3) forms of this KTPKKAKKP sequence to interact with plasmid DNA and to enhance transfection mediated by cationic liposomes and PEI, both in vitro and in vivo. To determine if the effect observed was linked with a particular conformation of the peptide, we tested a peptide H9-2 P → A in which the prolines were replaced by alanine residues to remove the ␤ turn structures described as probably involved in the interaction between H9-2 and DNA. 47 We also tested in in vitro transfection a peptide corresponding to the exact sequence of residues 147 to 160 from human histone (H14). In order to further define if peptide sequences were implicated in the transfection enhancement observed, we also studied poly-l-lysine peptides K10, K12 and K18 with respective residue numbers of 10 (the same total number of lysine as that contained in H9-2), 12 and 18, K18 being as long as the H9-2 peptide, but possessing a much higher density of positive charges. The nucleolin-derived (ATPAKKAA) 2 sequence (N8-2), which binds linear DNA without promoting any alteration in DNA conformation, 47 was also evaluated. We also tested the protamine-derived peptides Pr18 and Pr21, which provided a way to test arginine-containing cationic peptides as compared with the former lysinecontaining ones. Finally, since intracellular trafficking toward the nucleus is widely recognized as a limitation Peptides were synthesized using an ABI 431 A (Perkin-Elmer, Norwalk, CT, USA) synthesizer and purified by inverted-phase chromatography with a trifluoroacetate (TFA) gradient. After lyophilization, the TFA salts of the peptides were solubilized in water.
in nonviral gene transfer, we tested the effects of the addition of a SV40 nuclear localization sequence to the H9-2 peptide (nls-H9-2). The amount of peptide is expressed as a ratio of peptide (without salts)/DNA (weight/weight). For the monomeric, dimeric and trimeric forms of the KTPKKAKKP sequence, 1 w/w ratio corresponds to 0.98 nmol of monomer/g DNA, meaning about three nucleic acids per monomer, and 1.6 lysine residues per nucleotide. As we did not determine the pKa of the various amines, we will not speak of 'charge ratio'. A TFA-NH 4 (peptides are TFA salts) solution was used as a control in the transfection experiments. Interaction of the monomeric, dimeric and trimeric form of the KTPKKAPKKP peptide with plasmid DNA was analyzed by gel retardation assay. Plasmids were mixed with peptides in NaCl 150 mm, HEPES 5 mm pH 7.5 solutions. After 15 min of incubation, DNA-peptide samples were loaded on a 0.8% agarose gel. Starting from a 0.18 peptide/DNA (w/w) ratio, the H9-2 and H9-3 peptides were able to slow down plasmid agarose gel migration. Complete inhibition of migration occurred for values above 0.6 w/w. In contrast, the shorter monomeric form H9 could not induce any gel retardation, even at a peptide/DNA ratio superior to 2 w/w. Therefore, either the shorter H9 peptide bound to DNA without inducing any strong conformation modification, or H9 binding was not strong enough to be maintained in the electrophoresis condition. The K10, K12 and K18 as well as H9-2 P → A peptides were also able to induce gel retardation from a peptide/DNA ratio of 0.1 to 0.2 w/w.
To determine if peptide-induced gel retardation could be linked to the formation of peptide/plasmid particles, samples were analyzed by dynamic light scattering using a Coulter N4-plus apparatus (Marigny, France). Mixing DNA with peptide H9-2 at a ratio lower than 0.3 w/w did not lead to the observation of any sizable particle (detection limit: 3 nm). However, when this ratio was over 0.6 w/w, particles of an estimated size of about 700 nm were observed. Increasing amounts of peptides up to 6 w/w resulted in a very small increase in size (to 750-800 nm). Optical microscopy confirmed the presence of numerous particles of the expected size, with occasionally some larger particles. When cationic lipids are added to peptide/DNA complexes, particles around 300 nm are generated, which tend thereafter to aggregate into micron-sized large complexes.
Another method for monitoring changes in DNA conformation is to determine the ability of an intercalating agent such as ethidium bromide to bind to DNA. Addition of an increasing amount of H9-2, H9-3, K 12 or K 18 to ethidum bromide-incubated DNA decreased the fluorescence intensity due to the intercalated dye, whereas no fluorescence change was observed with the H9 monomeric form (Figure 1a) . The fluorescence decrease indicates that ethidium bromide is removed from DNA, either due to a DNA condensation state or to the fixation of peptides that hinder ethidium bromide access. Dimeric and trimeric forms of H9 peptide induced a similar reduction of fluorescence, starting from a peptide-to-DNA ratio of 0.3 (w/w). The RPR 115335 48 cationic lipid was also able by itself to induce a decrease in ethidium-bromide fluorescence, and ethidium bromide exclusion was more pronounced when both H9-2 peptide and RPR 115335 were present, although the additive effect was quite slight at high RPR 155335/DNA ratio ( Figure 1b) .
We then assessed if the conformational changes induced by the H9-2 and H9-3 peptides resulted in a protection of plasmid DNA from DNase I digestion. Addition of the H9-2 peptide at a ratio able to induce gel retardation resulted in a slight protection of DNA, and higher amounts could not provide complete protection ( Figure 2 , upper panel). We then tested the effects of peptide addition combined with cationic lipids. For these experiments, we use two new cationic lipids: RPR 115335 cationic lipid bears an original symmetric cationic head; RPR 120535 is a derivative of dioleoylglycylspermine (DOGS) with a linearly placed spermine cationic head; both, as DOGS, are able to transfect without the need to add DOPE 48, 49 (RPR 115335 is product 6 in Ref. 48 ). DNase protection studies using RPR 115335 added at a ratio used to transfect cells could restrict attack by DNase-I, but only partially, whereas RPR 120535 has a much better efficiency in protecting DNA ( Figure 2 , middle panel). When both components H9-2 (0.6 w/w) peptide and RPR 115335 (3 nmol/g DNA) were added sequentially to the plasmid, the resulting particle was completely resistant to DNase-I attack, indicative of a cooperative effect of both components for DNA protection ( Figure 2 ). Similar studies showed that the H9 monomeric form could not protect DNA.
Transfection efficacies in vitro are optimal with cells in exponential growth and in a serum-free and protein-free medium. As this can hardly be related to in vivo situations, we transfected confluent cells (2 days after seeding at 2.5 to 5 × 10 4 cells/cm 2 in 24-well dishes) and checked the influence of the presence of serum. Transfections were performed in quadruplicate and were always repeated at least three times. Each graph represents data obtained in a unique representative experiment.
When H9-2, nls-H9-2 or N8-2/pCMV-Luc plasmid 3 complexes at ratios from 0.1 to 4 (w/w) were added to NIH 3T3, 3LL and H460 cells, without addition of other transfection agents, the resulting luciferase activity was always null or very low. One of our starting hypotheses was that a DNA-compacting peptide could compensate for a relatively low cationic lipid:DNA ratio, 39 and could help in in vivo conditions requiring such low amounts of cationic lipid. 3 We therefore tested the effect of peptide addition before the addition of the cationic lipid DOGS used in an amount insufficient by itself to provide an optimal transfection of NIH 3T3 cells (Table 2 ). In such 'low lipid' transfection conditions, addition of the H9-2 and nls-H9-2 had a clear beneficial effect, increasing reporter gene activity up to that which is observed in an optimal transfection, whereas N8-2 and nls peptides induced a more modest enhancement.
To investigate if the addition of a DNA-compacting peptide could enhance transfection even with the optimal use of transfection agents, we tested various ratios of cationic lipid or polymer. For easily transfected cells such Table 2 , except for the amount of DOGS. Transfection of NIH 3T3 cells was performed in the absence of serum. Results are expressed as the average enhancement over the results obtained in the absence of peptide. Peptides from a 1 mg/ml stock solution were added to pCMV-Luc plasmid in saline 15 min before the addition of an equal volume of DOGS in saline, for a final 1.8 nmol DOGS/g DNA. Cells were washed three times with serum-free medium, and incubated in 250 l serum-free medium in which 50 l of transfection mix (0.25 g DNA per cm) was poured. Serum was added to the cells 4 h after transfection and the medium changed the day after. Luciferase activity was assessed 48 h after transfection, using Promega luciferase assay system (Promega, Madison, WI, USA) and a Lumat LB 9501 (Berthold, Evry, France) luminometer (integration time 10 s after the addition of 50 l of substrate to 10 l of the cell lysate). Calibration performed with purified luciferase protein established that 10 6 RLU were approximately equivalent to 15-50 pg luciferase (Sigma, St Louis, MO, USA, and Boehringer, Mannheim, Germany). Expression of the results as luciferase activity per mg protein can artificially favor toxic transfection procedures that significantly decrease cell viability. We therefore chose to express the results as relative light units (RLU) per transfected well.
as NIH 3T3, the H9-2 peptide produces only a weak increase on transfection, up to two-to four-fold, when DOGS, or RPR 120535, or LipofectAMINE were used at optimal lipid:DNA ratio. These results are similar to those described by other groups. 41, 42 However, for cells
DNA-condensing peptides for transfection
that are more difficult to transfect such as 3LL and H460 lung carcinoma cells, addition of H9-2 and nls-H9-2 peptides had a clear and drastic beneficial effect, whereas nls peptide alone did not produce any marked transfection enhancement ( Figure 3) . Similarly, N8-2 peptide did not increase DOGS transfection efficiency (data not shown).
As controls, addition of NH 4 -TFA salts in amounts equivalent to those provided by the addition of the peptides, or addition of the peptides after the addition of cationic lipid in the transfection mix, or addition of the peptide directly to the cell separately from the transfection mix, all failed to enhance transfection. Most in vivo applications of gene transfer need to stand up to seric factors. We tested the ability of precompaction with the peptides to enhance serum resistance, using different cationic transfection agents: LipofectAMINE (Life Figure 4 H9-2 Technologies, Gaithersburg, MD, USA), a DOSPA cationic lipid that provides efficient transfection when combined to DOPE, DOGS, RPR 115335 and RPR 120535 which can transfect without DOPE, and show different strengths in their interaction with DNA; and the cationic polymer polyethylenimine: PEI 50 kDa (Fluka, Ronkonkoma, NY, USA) and 800 kDa (Sigma, St Louis, MO, USA), used as described in Ref. 35 . The composition of the mixing solution containing the plasmid was optimized for each cytofectant. As shown in Figure 4 , the transfection of rabbit smooth muscle cells mediated by cationic lipids (LipofectAMINE, RPR 115335 and RPR 120535) and by PEI was drastically inhibited in the presence of serum. Addition of H9-2 peptide to the plasmid before the addition of synthetic vectors drastically reduced this serum inhibition. This result was also confirmed with DOGS and with various cytofectant:DNA ratios, on various cell types (3LL, H460, NIH 3T3, H1299). A similar experiment with a ␤-galactosidase encoding plasmid (pCMV LacZ 3 ) on various cell lines indicated that precompaction by H9-2 induced an increase in the number of cells containing detectable amounts of reporter protein after X-gal staining 50 ( Figure 5 ). Both H9-2 and H9-3 were similar in their ability to promote transfection in the presence of serum, whereas H9 was ineffective (Figure 6a and b ). An equivalent transfection enhancing potency was observed with the proline to alanine mutant peptide H9-2 P → A, the intermediate size H14, and the nls-H9-2 peptide bearing an additional nuclear localization sequence (data not shown). On the other hand, the nls sequence alone did not have any transfection enhancing property. We also tested different poly-l-lysines: K10 and K12 showed a reduced potential, whereas K18 behaved similarly to H9-2, as it did in the gel retardation and ethidium bromide fluorescence experiments (data not shown). Protamine-derived Pr18 and Pr21 peptides displayed a similar potential to increase transfection as H9-2 ( Figure 6c ).
We then evaluated whether precondensation of plasmid DNA with a peptide could modify the intracellular trafficking of the DNA/lipid particles. A fluorescently labeled plasmid was either precondensed with H9-2 or not (peptide:DNA ratio of 2 w/w), then complexed with RPR 120535 cationic lipid and the mix was exposed to cells for 24 h in the presence of serum. In the absence of peptide, plasmid DNA was present in 100% of cells, displaying a punctuate cytoplasmic staining, mostly in the perinuclear region ( Figure 7D ). This pattern of fluorescence was similar to that observed when cells were exposed to fluorescently labeled dextran, a polymer which is endocytosed and delivered to the lysosomal compartment (data not shown). On the other hand, when plasmid DNA was precondensed with the H9-2 peptide, the pattern of fluorescence observed in cells was clearly different ( Figure 7C ). Some cells contained no plasmid, but the majority of the cells exhibited a few large intensely stained plasmid-containing vesicles. Thus, precondensation of plasmid by H9-2 peptide clearly modified the intracellular trafficking of the plasmidcontaining particles.
Effect of addition of H9-2 peptide on the gene transfer mediated by RPR 115335 and PEI was assessed after direct injection into Lewis lung carcinoma (3LL) tumor. This tumor grows very fast on C57BL6 mice and is highly necrotic. In this model, injection of naked pCMV-Luc plasmid does not induce any luciferase expression above background (data not shown). As shown in Figure 8a , addition of H9-2 enhanced the expression of luciferase activity. The use of nls-H9-2 did not show any clear advantage of the additional nuclear localization sequence: over three experiments, the mean enhancement observed was below statistical significance.
PEI 50K was more efficient than PEI 800K to transfect 3LL tumors, but both provided very low levels of transfection, typically two to four animals in series of 10 providing a signal above background (Figure 8b ). Addition of H9-2 peptide with PEI 50K or 800K resulted in approximately 50% of tumors positive for luciferase activity with PEI 800K, and nearly 100% with PEI 50K, but always with a limited luciferase activity as compared with the values obtained with RPR 115335 combined with H9-2 (Figure 8b and legend) . Tested in similar conditions, nls-H9-2 leads again to results similar to H9-2 (data not shown).
In vitro transfection of cultured cells always requires, as a first step, plasmid complexation with a synthetic cationic carrier. For most vectors, high efficiency in vitro transfection correlates with a global excess of cationic charges. 51, 52 However, this excess of cationic charges could in vivo facilitate nonspecific interaction with many undesired elements such as extracellular matrix, and negatively charged serum components, such as albumin. This latter assumption seems supported by the low in vitro transfection activity of highly cationic DNA vector/particles in the presence of serum 53 ( Figure 7 ). Indeed, it has been shown in a mouse brain model that particles formed with a limited number of cationic lipids could be more efficient than highly charged particles. 3 Moreover, cationic lipids have been shown to have other negative effects such as inflammatory potency and complement activation. 46 In this study, we have attempted to achieve a precondensation of the plasmids before the addition of cationic lipids or polymer. The idea was to precompact DNA so as to protect it from nuclease degradation, neutralize some of its charges and form a core of virus-like nucleoproteic particles that would thereafter be coated with the cationic lipid. The precompacting step would thus reduce the need for a large amount of cationic lipid, 39 thereby limiting the toxicity of such products. Instead of the commonly used poly-l-lysine, long synthetic polypeptides or endogenous proteins, we tested as short peptides as possible that were derived from human proteins. Our aim was to define elements of DNA delivery easier to produce and characterize, and which could be linked to additional functions such as a nuclear localization sequence, or other targeting or fusigenic moieties.
We show here that lysine-or arginine-rich cationic pep- tides derived from histone and protamine can indeed help for in vitro and in vivo transfection. This effect is not dependent upon the cell line used, and can be observed with various cationic lipids such as DOGS, LipofectAM-INE RPR 115335 and RPR 120535, and even with the polymer polyethylenimine. For transfections performed in a serum-free medium, this enhancement is moderate for easily transfected cells at an optimal cationic lipid or PEI:DNA ratio but it is more pronounced for cells that are difficult to transfect. The peptide-induced enhancement is drastic when the transfection is performed in the presence of serum, bringing the luciferase expression signal to the same level as in serum-free transfection. This increase in reporter gene activity was correlated with a greater number of ␤-galactosidase expressing cells, indicating either that more cells were able to express the foreign gene, or that more cells expressed it enough to reach detection level. In a similar experiment using polylysine to precondense DNA, it has been shown that such an effect could be related to an increase of DNA uptake by the cells 13 and by a greater number of cells internalizing the complexes. 13, 41 The beneficial effect of the H9-2 histone-derived peptide was also observed in vivo in the 3LL tumor model. Gene transfer in this model requires a high ratio of cationic lipid to DNA, and addition of the H9-2 peptide to plasmid DNA before the addition of RPR 115335 led to an eight-fold increase in reporter gene activity.
Addition of these cationic peptides could help to reduce the number of cationic lipids needed for optimal transfection, somehow contributing to the total cationic charges required. Indeed, cationic peptides were allowed to attain reasonable transfection levels at low cationic lipid or PEI:DNA ratio, both in vitro and in vivo ( Figure  6 and Figure 8 ). On the other hand, the highest reporter gene activities using a combination of peptide and cationic lipid were always higher than those obtained by using a cationic lipid alone, even at optimal ratio ( Figure   6 and Figure 8 ). This demonstrates that the precompacting cationic peptide not only plays a role in increasing cationic charges, but also acts synergistically with the cationic lipid to enhance gene transfer. This observation is further supported by the structureactivity relationship study: when testing peptides of various size and charge, the enhancement of transfection correlated with the ability to condense DNA, as revealed by gel retardation and ethidium bromide exclusion. Therefore, the structure of the peptide is important: cationic peptides which do not associate with DNA, or associate with DNA but do not interact strongly enough to induce DNA condensation such as N8-2, whatever the ratio used, do not enhance the transfection efficiency of cationic lipids, although they provide additional cationic charges. Thus, a structural modification of the DNA-containing complexes must take place. Length and charge density might be important, since the H9 peptide (9 aa) bearing five lysines and the N8-2 peptide (16 aa) bearing eight lysines were both insufficient to condense plasmid and to provide any enhancement of gene transfer efficiency in vitro. This enhancement required at least 12 or 14 amino acids, with an average of 50-60% of the residues being lysines.
We synthesized a peptide in which the proline residues from H9-2 were replaced by alanine, to test the hypothesis formulated by Erard et al 47 of a possible role of the proline-induced ␤-turns in the ability of the peptide to condense DNA. This replacement did not modify the ability of the peptide to confer serum-resistant transfection efficiency to the nucleolipidic particles. This result, as well as the fact that many different peptides, either lysine-rich or arginine-rich, display similar behavior, indicates that the primary sequence of the peptide is of little effect, as long as the peptide bears a high enough ratio of cationic charges distributed on a long enough backbone. This seems consistent with the fact that condensation of DNA by larger basic proteins does not depend on protein composition. 15 However, because of the risk inherent to peptides of inducing an immunological response, we favored the use of sequences derived from endogenous proteins. Further experiments will still be necessary to measure precisely the potential of our peptides to elicit immune recognition, but preliminary results indicate the absence of immune response to mouse histone after repeated administration of H9-2/ DNA/cationic lipid particles (data not shown).
In vitro resistance to serum might be relevant to the in vivo transfecting efficiency of a particle, as is suggested here in the case of the experimental Lewis lung carcinoma model. However, the exact nature of the modification in the lipoplex structure induced by the preaddition of a DNA-condensing peptide remains to be analyzed. An important modification might be a more dense organization of the DNA within the particle. We also show that one of the measurable effects of DNAcondensing peptide addition is the acquisition of resistance to nuclease attack in vitro, which might be correlated with in vivo protection of DNA against endogenous DNases or against other nonspecific interaction which could inhibit transfection.
Other factors that might be modified by the addition of a DNA-compacting peptide are the size of the DNAvector particle, its zeta potential, and the organization of the DNA inside the complex. By fluorescence microscopy, we showed that preaddition of DNAcondensing peptide in the transfection particles led to a modification of the intracellular fate of the particles when the transfection was performed in the presence of serum. We have previously found a correlation between the intracellular fluorescent pattern of labeled complexes internalized by the cells and the gene transfer efficiency. 53 In this former study, we suggested that the structural characteristics of a cationic lipid/DNA complex interacting with the cell membrane might particularly influence the way it will be taken up and determine its intracellular fate. In this study, we have found that the use of a compacting peptide leads to large intracellular DNA complexes, presumably vesicles. These large vesicles might be more easily destabilized by transfecting complexes than classical endosomes, whose content is generally rapidly eliminated by endosome fusion with lysosomes.
The addition of a DNA condensing peptide to the plasmid might also tentatively help its traffic to the nucleus. When we associated a nuclear localization sequence derived from SV40 to the H9-2 peptide, in vitro and in vivo data failed to show any beneficial advantage of this sequence. However, the H9-2 peptide, rich in lysine, might per se be directed towards the nucleus, thereby limiting the effect of an additional nls sequence. The relevance of all these factors has to be established.
In conclusion, DNA precondensation by a nontoxic and chemically synthesized short endogenous peptide might represent significant progress in cationic lipidmediated gene delivery. Future improvement might result from a better understanding and control of cellular events such as plasmid passage of the cell membrane and nuclear envelope, or plasmid DNA cytosolic traffic.
